Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
CANF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $4.69
Previous CloseN/A
Volume35.97K
Average Volume (3M)265.50K
Market Cap
$15.77M
Enterprise ValueN/A
Total Cash (Recent Filing)$3.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 29, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding10,353,088
10 Day Avg. Volume112,044
30 Day Avg. Volume265,500
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)57.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside609.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Can-Fite BioPharma News
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $1.29 and its highest was $4.69 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $15.77M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is May 29, 2025 which is in 50 days.
How were Can-Fite BioPharma’s earnings last quarter?
Currently, no data Available
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.24.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 10,353,088 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
---
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
---
CANF Stock 12 Month Forecast
Average Price Target
$10.00
▲(609.22% Upside)
Technical Analysis
Best Analysts Covering CANF
1 Year
1 Year Success Rate
4/34 ratings generated profit
1 Year Average Return
-42.91%
reiterated a buy rating 3 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -42.91% per trade.
---